Generics giants jostle over pain drug


The US Food and Drug Administration (FDA) has approved the first batch of generic competitors to Pfizer’s non-steroidal anti-inflammatory Celebrex (celecoxib). Teva received approval for its 50, 100, 200 and 400mg doses, and Mylan also had its 50mg dose approved. Actavis, which was also in the running, is yet to receive final approval for any of its celecoxib generics.

The agency has also granted Teva 180 days’ market exclusivity for all but the 50mg form, under US provisions designed to encourage generic competition. Both Mylan and Actavis have attempted to sue the FDA for this decision, which Mylan has called an ‘unprecedented error’ and Actavis described in a statement as ‘arbitrary, capricious and contrary to law’. The court denied Mylan’s injunction, but the company has signalled its intention to appeal that decision.

Mylan has also negotiated an agreement with Pfizer to launch its generic versions in December 2014, or earlier under certain conditions. All three companies now have such agreements in place.


Related Content

Generics triumph in anti-inflammatory patent battle

25 April 2014 Business

news image

Pfizer settles deals to allow copycat celecoxib

Business roundup

27 January 2012 Business

news image

Industry news, February 2012

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint